Latest news with #Proteomics
The Age
2 days ago
- Business
- The Age
$6M boost to drive industrial-scale Proteomics facility in WA
Proteomics International will expand its Perth facility into a national diagnostics hub using a $6 million funding boost to develop a new protein biomarker analysis platform for industrial-scale precision medical and agricultural screening. The company will partner with The University of Western Australia (UWA), the Western Australian Government and life science research collaborator BioPlatforms Australia to develop its world-class Perth facility. The partners want to target a growing market for high-throughput precision diagnostics across medicine and agriculture. Proteomics and UWA will each kick $1 million into the kitty for the three-year project to develop an accredited protein biomarker analysis platform capable of helping push advances in the two critical sectors. The Proteomics and UWA laboratories collaborate to bring together scientific and technological know-how to tease out the answers to everyday problems in health, agriculture and environmental sciences respectively, focusing on the emerging proteomics field. Proteomics researchers work on identifying and measuring the changes in proteins within cells. Unlike DNA, proteins can change - studying them allows scientists to develop diagnostic tests that can detect diseases earlier and allow doctors to tailor treatments to their patients. 'This facility can become a national hub for precision diagnostic testing across clinical and agricultural proteomics.' Proteomics International managing director Dr Richard Lipscombe In agriculture, it could be used to guide grain selection or sowing decisions to improve yield and sustainability, for example. This may become particularly significant given the world's growing population and drying climate, which means farmers must increasingly work to maximise yields while they safeguard crops against drought, salinity, weeds and pests. Proteomics International managing director Dr Richard Lipscombe said: 'This facility can become a national hub for precision diagnostic testing across clinical and agricultural proteomics. Extending our recent successful capital raise with state-of-the-art infrastructure to analyse thousands of samples at industrial scale, we can turn biological insight into real-world solutions - whether that's improving outcomes for patients with chronic diseases or selecting better crop varieties to address food security.' Proteomics says achieving a new nationally accredited technology platform would significantly boost the facility's capacity for fast and accurate screening, help roll out diagnostic tests for clinical use and enable it to test large sets of agricultural and environmental samples.
Sydney Morning Herald
2 days ago
- Business
- Sydney Morning Herald
$6M boost to drive industrial-scale Proteomics facility in WA
Proteomics International will expand its Perth facility into a national diagnostics hub using a $6 million funding boost to develop a new protein biomarker analysis platform for industrial-scale precision medical and agricultural screening. The company will partner with The University of Western Australia (UWA), the Western Australian Government and life science research collaborator BioPlatforms Australia to develop its world-class Perth facility. The partners want to target a growing market for high-throughput precision diagnostics across medicine and agriculture. Proteomics and UWA will each kick $1 million into the kitty for the three-year project to develop an accredited protein biomarker analysis platform capable of helping push advances in the two critical sectors. The Proteomics and UWA laboratories collaborate to bring together scientific and technological know-how to tease out the answers to everyday problems in health, agriculture and environmental sciences respectively, focusing on the emerging proteomics field. Proteomics researchers work on identifying and measuring the changes in proteins within cells. Unlike DNA, proteins can change - studying them allows scientists to develop diagnostic tests that can detect diseases earlier and allow doctors to tailor treatments to their patients. 'This facility can become a national hub for precision diagnostic testing across clinical and agricultural proteomics.' Proteomics International managing director Dr Richard Lipscombe In agriculture, it could be used to guide grain selection or sowing decisions to improve yield and sustainability, for example. This may become particularly significant given the world's growing population and drying climate, which means farmers must increasingly work to maximise yields while they safeguard crops against drought, salinity, weeds and pests. Proteomics International managing director Dr Richard Lipscombe said: 'This facility can become a national hub for precision diagnostic testing across clinical and agricultural proteomics. Extending our recent successful capital raise with state-of-the-art infrastructure to analyse thousands of samples at industrial scale, we can turn biological insight into real-world solutions - whether that's improving outcomes for patients with chronic diseases or selecting better crop varieties to address food security.' Proteomics says achieving a new nationally accredited technology platform would significantly boost the facility's capacity for fast and accurate screening, help roll out diagnostic tests for clinical use and enable it to test large sets of agricultural and environmental samples.
The Age
3 days ago
- Health
- The Age
Milestone first patent for Proteomics simple endometriosis test
In a milestone moment, ASX-listed diagnostics innovator Proteomics International Laboratories has achieved its first patent globally in Japan for its simple 'traffic light' diagnostic blood test for endometriosis. The decision will protect the company's intellectual property rights for its PromarkerEndo technology in the world's fourth-largest healthcare market until March 16, 2041. Proteomics says Japan's healthcare sector already widely uses in vitro diagnostics and precision medicine technologies to customise treatments for patients and help deliver better patient outcomes. The company is planning to start an international commercial roll-out of the device within months using its existing direct-to-consumer channels, while also tapping into general practitioners and women's health specialists. 'This is a significant achievement because it validates the novelty of PromarkerEndo, our world-first blood test for endometriosis.' Proteomics International managing director Dr Richard Lipscombe Proteomics International managing director Dr Richard Lipscombe said: 'Securing patent protection for our diagnostic technology in this region is a key step in our global commercialisation pathway and provides a strong foundation for potential partnerships, licensing, and regulatory advancement.' PromarkerEndo promises to revolutionise women's reproductive healthcare by delivering the first clinically viable, real-world, non-invasive diagnostic test for a disease affecting one in nine women and girls. Estimates suggest endometriosis costs the Australian economy nearly $10 billion annually. Its symptoms can be devastating for women, but it has historically been difficult to diagnose. It can take up to seven years on average for women to be diagnosed with endometriosis, using painful and invasive laparoscopy and tissue biopsies, performed under anaesthetics. For the first time, doctors may instead be able to turn to PromarkerEndo as a frontline tool in detecting endometriosis in symptomatic patients. The device uses a universal 'traffic light' risk score - low, moderate or high - to indicate a patient's likelihood of having the disease.
Sydney Morning Herald
3 days ago
- Health
- Sydney Morning Herald
Milestone first patent for Proteomics simple endometriosis test
In a milestone moment, ASX-listed diagnostics innovator Proteomics International Laboratories has achieved its first patent globally in Japan for its simple 'traffic light' diagnostic blood test for endometriosis. The decision will protect the company's intellectual property rights for its PromarkerEndo technology in the world's fourth-largest healthcare market until March 16, 2041. Proteomics says Japan's healthcare sector already widely uses in vitro diagnostics and precision medicine technologies to customise treatments for patients and help deliver better patient outcomes. The company is planning to start an international commercial roll-out of the device within months using its existing direct-to-consumer channels, while also tapping into general practitioners and women's health specialists. 'This is a significant achievement because it validates the novelty of PromarkerEndo, our world-first blood test for endometriosis.' Proteomics International managing director Dr Richard Lipscombe Proteomics International managing director Dr Richard Lipscombe said: 'Securing patent protection for our diagnostic technology in this region is a key step in our global commercialisation pathway and provides a strong foundation for potential partnerships, licensing, and regulatory advancement.' PromarkerEndo promises to revolutionise women's reproductive healthcare by delivering the first clinically viable, real-world, non-invasive diagnostic test for a disease affecting one in nine women and girls. Estimates suggest endometriosis costs the Australian economy nearly $10 billion annually. Its symptoms can be devastating for women, but it has historically been difficult to diagnose. It can take up to seven years on average for women to be diagnosed with endometriosis, using painful and invasive laparoscopy and tissue biopsies, performed under anaesthetics. For the first time, doctors may instead be able to turn to PromarkerEndo as a frontline tool in detecting endometriosis in symptomatic patients. The device uses a universal 'traffic light' risk score - low, moderate or high - to indicate a patient's likelihood of having the disease.
The Age
05-06-2025
- Health
- The Age
New Proteomics blood test unlocks better oesophageal cancer detection
Newly published results from ASX-listed diagnostics trailblazer Proteomics International Laboratories have unveiled stunning new clinical findings for its simple PromarkerEso oesophageal cancer blood test, opening the way for the innovative blood test to be commercially released. The test's accuracy was demonstrated in a 259-person study across three patient groups in Australia and the United States. The results were posted overnight in the peer-reviewed journal Proteomes, providing a major academic rubber stamp for the technology. The new findings showed that the test could detect a whopping 91.4 out of 100 patients with the heartburn-related cancer and correctly identify 98.9 per cent of people without it, offering a powerful, non-invasive alternative to costly and uncomfortable endoscopies. Based on the results, PromarkerEso outperforms many tests currently used for screening other types of cancers. For context, the widely used Prostate-Specific Antigen blood test used to diagnose prostate cancer has an Area Under Curve (AUC) measurement of just 0.68, while PromarkerEso hit an exceptional AUC of 0.98. An AUC greater than 0.7 is considered to offer acceptable discrimination, while above 0.9 is considered outstanding. 'The published results represent a major advancement in our mission to transform the lives of people living with chronic acid reflux.' Proteomics International Laboratories managing director Dr Richard Lipscombe Described by the company as a landmark moment in non-invasive diagnostics, PromarkerEso uses a standard blood draw to flag at-risk patients using a traffic light system that grades patients at low, moderate and high risk of developing the cancer. The results are delivered with near-laboratory precision and without the need for specialist procedures. Proteomics says the breakthrough could transform early detection of one of the world's deadliest and most overlooked cancers, which often goes undiagnosed until it's too late. Specifically, the disease targeted by the test is oesophageal adenocarcinoma, which is often caused by chronic heartburn, or acid reflux, and affects up to 20 per cent of people in Western populations. Despite the high incidence, current detection methods rely on invasive endoscopy procedures that are uncomfortable and expensive. In the US, an endoscopy costs about US$2750 (A$4200) per procedure. Even with this rigorous scrutiny, up to 90 per cent of cases go undetected.
